ClinicalTrials.gg
TerminatedNCT07085468Updated Sep 21, 2026Results posted

A Study of LY3549492 in Healthy Weight Adult Participants

A Phase 2 interventional study of LY3549492 and Placebo in Healthy, sponsored by Eli Lilly and Company. Terminated at 21 sites in 2 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Basic science

Why this study was terminated
Study terminated for strategic business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 280 studies in Body Weight with a site in United States — 33 open to participants now, 50 under way, 6 of them phase 3. Body Weight · United States.

Enrollment
238th of 242
1 · median 65
Started
2025
with 9 others
Phase 2
15 of 280
2 open now
Registered
259th of 280
by date

Among the 280 studies in Body Weight with a site in United States, this one is the 238th largest by enrollment of the 242 interventional ones that give a count, is one of 10 that started in 2025, is one of 15 in phase 2, and was the 259th registered.

Body Weight

658 studies on the registry are indexed under Body Weight; 77 are open to participants now.

Browse Body Weight studies →

Open to participants now

33 of the 280 studies in Body Weight with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Body Weight studies recruiting now, 22 (41%) set no upper age limit and 30 (56%) stop at 75 or younger; 6 take children under 18; 16 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 280 studies in Body Weight with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Elderly
  • Body Weight
  • Body Composition
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
  • Have had a stable body weight for 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes, latent diabetes in adults, or a history of ketoacidosis or hyperosmolar coma
  • Have:

    • type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
    • rare forms of diabetes mellitus, or
    • (HbA1c) >8%
  • Have poorly controlled hypertension
  • Have any of the following cardiovascular conditions within 12 months prior to screening:

    • acute myocardial infarction
    • stroke
    • unstable angina, or
    • hospitalization due to congestive heart failure.
  • Have a history of Functional Classification III or IV congestive heart failure
  • Have signs and symptoms of liver disease
  • Have a history of pancreatitis
  • Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    15 mg LY3549492

    Participants were planned to receive 15 milligrams (mg) LY3549492 orally once daily for 48 weeks.

    Drug: LY3549492

  • Experimental
    60 mg LY3549492

    Participants were planned to receive 60 mg LY3549492 orally once daily for 48 weeks.

    Drug: LY3549492

  • Placebo comparator
    Placebo

    Participants were planned to receive matching placebo orally once daily for 48 weeks.

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through Week 48

Secondary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 24, Week 48

  2. Number of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal

    Time frame: Baseline through Week 48

07

Results

Posted Sep 21, 2026
Limitations and caveats
The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected and no analyses could be performed.

Participant flow

The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected and no analyses could be performed.

Participant flow — Overall Study
Milestone15 mg LY354949260 mg LY3549492Placebo
Started010
Completed000
Not completed010

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time frame:
Baseline through Week 48

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Body Weight
Time frame:
Baseline, Week 24, Week 48

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal
Time frame:
Baseline through Week 48

No measurements were reported for this outcome.

Adverse events

Collected over All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
15 mg LY3549492———
60 mg LY3549492———
Placebo———

Baseline characteristics

All enrolled participants.

Age, Categorical
Age, Categorical(Participants)15 mg LY354949260 mg LY3549492PlaceboTotal
<=18 years0000
Between 18 and 65 years0000
>=65 years0101
Sex: Female, Male
Sex: Female, Male(Participants)15 mg LY354949260 mg LY3549492PlaceboTotal
Female0000
Male0101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)15 mg LY354949260 mg LY3549492PlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino0101
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)15 mg LY354949260 mg LY3549492PlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0101
More than one race0000
Unknown or Not Reported0000
08

Study locations

21 sites
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Great Lakes Clinical Trials - Andersonville
    Chicago, Illinois 60640, United States
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Viacar Recherche Clinique
    Greenfield Park, J4V 2G8, Canada
  • Apex Trials
    Guelph, N1G 0B4, Canada
  • OCT Research ULC
    Kelowna, V1Y 1Z9, Canada
  • Clinique Mémoire de Montréal
    Montreal, H3G 1H9, Canada
  • Ottawa Memory Clinic
    Ottawa, K1Z 1G3, Canada
  • Richmond Clinical Trials
    Richmond, V6V 2L1, Canada
  • Q&T Research Sherbrooke Inc.
    Sherbrooke, J1J 2G2, Canada
  • Toronto Memory Program
    Toronto, M3B 2S7, Canada
  • BioPharma Services
    Toronto, M9L 3A2, Canada
  • Diex Recherche Trois-Rivieres
    Trois-Rivières, G9A 4P3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2025, 0 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartActual
Jul 21, 2025
Primary completionActual
Aug 14, 2025
CompletionActual
Aug 14, 2025
Results first posted
Sep 21, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07085468
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jul 21, 2025
Primary completion
Aug 14, 2025
Completion
Aug 14, 2025
Results posted
Sep 21, 2026
Last update
Sep 21, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naperiglipron

Start the discussion